Ethnic variability in warfarin maintenance in the community setting: A population-based study in a managed care environment in Israel

Israel Medical Association Journal

Volumn 9, Issue 1, 2007, Pages 12-15

  Hekselman, Igal ^a,b   Kahan, Natan R ^c   Ellis, Martin ^b,d   Kahan, Ernesto ^b  

^a CLALIT HEALTH SERVICES   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d MEIR MEDICAL CENTER   (Israel)

Author keywords

Ethnicity; International normalized ratio; Managed care; Thrombosis; Warfarin

Indexed keywords

WARFARIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARAB; ARTICLE; CHILD; COMMUNITY CARE; CONTROLLED STUDY; CULTURAL FACTOR; ETHNICITY; FEMALE; HUMAN; INFANT; INTERNATIONAL NORMALIZED RATIO; ISRAEL; JEW; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; PATIENT COMPLIANCE; POPULATION BASED CASE CONTROL STUDY; SEX DIFFERENCE; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ARABS; COMMUNITY HEALTH SERVICES; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; ISRAEL; JEWS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; WARFARIN;

EID: 33846428434     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW. Melmon and Morelli's Clinical Pharmacology. 4th edn. New York: McGraw Hill, 2000.
2. British Committee for Standardisation in Haematology. Guidelines on oral anti-coagulation. 2nd edn. J Clin Pathol 1990;43:177-83.
3. Health Care Guidelines: Anticoagulation Therapy Supplement. Institute for Clinical Systems Improvement. www.icsi.org.
4. Anderson RJ. Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. J Manag Care Pharm 2004;10:159-65.
5. Costa IM, Scares PJ, Afonso M, Ratado P, Lanao JM, Falcao AC. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol 2000;52:1405-10.
6. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-2.
7. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimum therapeutic range. Chest 2001;119:8-21S.
8. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation, Arch Intern Med 2000;160:967-73.
9. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 2005;39:1008-12.
10. Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999,107:207-9.
11. Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004;103:2630-5.
12. Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005;77(5):365-72.
13. A short history and useful factoids about warfarin (Coumadin). www.flounder.com/warfarin.htm
14. Baron-Epel O, Haviv-Messika A, Tamir D, Nitzan-Kaluski D, Green M. Multiethnic differences in smoking in Israel: pooled analysis from three national surveys. Eur J Public Health 2004;14:384-9.
15. Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ. Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 2004;4:395-401.